|
|
Darryl Strawberry touts new medicines developed in New York |
Date:14-May-2010
May 11, 2010 | 04:09 PM
"I'm bringing hope to people by telling them it works," said four-time World Series Champion and two-time colon cancer survivor, Darryl Strawberry, referring to modern drugs and treatment in an event hosted by The Pharmaceutical Research and Manufacturers of America (PhRMA) along with New York Biotechnology Association (NYBA), to showcase a report that shows more than 700 medicines in development by New York companies.
The report, Medicines in Development: New York 2010, prepared by PhRMA, outlines 722 new medicines that are being developed by New York companies to treat major chronic diseases such as heart disease, cancer, stroke, diabetes, and Alzheimer's diseases among others.
"The biggest budget buster of all is the cost of fighting chronic diseases," said Ken Johnson, PhRMA's senior vice president.
According to Johnson, in New York the cost of fighting chronic diseases is $90 billion a year.
"My life was saved and I believe other lives can be saved if they are aware of research and the new medicines that come along for people," said Strawberry. "We have to bring hope."
Johnson said these new medicines will not only help patients suffering from diseases, but pointed out the pharmaceutical research and biotechnology companies' impact on the state's economy.
"If we want to improve the economic condition of this state it important to improve the health conditions of New Yorkers and Americans," said Johnson.
According to Nathan Tinker executive director of NYBA, there are about 55,000 people employed in New York in the bio-pharmaceutical industry and indirectly, the industry has generated employment of about 250,000 more workers, he said.
|
|
